FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety

Immunomodulatory monoclonal IgG1 antibodies developed for cancer and autoimmune disease have an inherent risk of systemic release of pro-inflammatory cytokines. In vitro cytokine release assays are currently used to predict cytokine release syndrome (CRS) risk, but the validation of these preclinica...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:MAbs
Main Authors: Alakhras, Nada S., Qiu, Jiabin, Rocha, Guilherme V., Witcher, Derrick R., Koester, Anja, You, Jinsam, Schaer, David A., Holmgaard, Rikke B., Driscoll, Kyla, Willy, Jeffrey A., Malherbe, Laurent P.
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2018
Assuntos:
Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6152447/
https://ncbi.nlm.nih.gov/pubmed/29953319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2018.1474996
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares